Rosiglitazone Adjunctive Therapy for Severe Malaria in Children
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Malaria
- Focus Biomarker; Pharmacodynamics
- Acronyms ROSI
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 26 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 31 Mar 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Mar 2020.